Last reviewed · How we verify
CYCLOSPORINE VS INFLIXIMAB
This is a comparative study evaluating cyclosporine (a calcineurin inhibitor) versus infliximab (a TNF-alpha inhibitor) for inflammatory bowel disease.
This is a comparative study evaluating cyclosporine (a calcineurin inhibitor) versus infliximab (a TNF-alpha inhibitor) for inflammatory bowel disease. Used for Inflammatory bowel disease (Crohn's disease and ulcerative colitis), Severe steroid-refractory IBD.
At a glance
| Generic name | CYCLOSPORINE VS INFLIXIMAB |
|---|---|
| Also known as | Cyclosporine (IV)= Brand Name = Sandinuum, Cyclosporine (PO)= brand name = Neoral, Infliximab (IV)= brand name= Remicade |
| Sponsor | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives |
| Drug class | Immunosuppressant (cyclosporine); TNF-alpha inhibitor (infliximab) |
| Target | Calcineurin (cyclosporine); TNF-alpha (infliximab) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Cyclosporine suppresses T-cell activation by inhibiting calcineurin and blocking IL-2 production, while infliximab is a chimeric monoclonal antibody that binds and neutralizes tumor necrosis factor-alpha (TNF-α), a key pro-inflammatory cytokine. Both agents reduce intestinal inflammation but through distinct immunological mechanisms.
Approved indications
- Inflammatory bowel disease (Crohn's disease and ulcerative colitis)
- Severe steroid-refractory IBD
Common side effects
- Nephrotoxicity (cyclosporine)
- Hypertension (cyclosporine)
- Infections (both agents)
- Infusion reactions (infliximab)
- Hepatotoxicity
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: